Reddit Posts
7 Undervalued Penny Stocks With Major Upside
Biotechs With Potential Catalysts This Week: $SPPI $VSTM $APRE $CAPR $CFMS
My Top Biotech Plays to get your Account Positive by the Years End
$CAPR - stock is hovering around $4 bucks. They just signed a worldwide licensing deal with John’s Hopkins University for their exosome technology. They’re leaders in DMD treatment and and future COVID vaccines. This thing should be trading at $12 bucks minimum right now. $100+ in coming years. BULL
Mentions
Shekreli says short CAPR
$CAPR will fail, and in a few days will release crucial news. little short play, down 19%. biotech (shkreli endorsed). [https://x.com/anthonystaj/status/1992972618077528196?s=20](https://x.com/anthonystaj/status/1992972618077528196?s=20)
I’ve been trading with my IRA that is sub $100k. I never use the entire thing for day trading or non-long term investing and actually I have like 20-30% of my account sitting in cash (which is actually is kind of a waste). I never put all my eggs in one basket. Now with this Ai bubble bursting I’m at 99% cash. Also, CAPR has been looking good for a short squeeze.
How confident are you that the upcoming P3 data will hit primary PUL (and key secondary LVEF) stat sig? I rolled most of my VRNA winnings into AVXL options and got burned badly upon CHMP negative opinion. I have a sizeable position in CAPR but now I am thinking if I should exit. If PUL does not hit, CAPR is most likely over. No way Vinay Prasad shows flexibility that Linda hopes the FDA shows as communicated in her last conference call.
Time to buy $CAPR. We bought 500,000 shares.
Buying more Capricor Therapeutics $CAPR been fully dollar cost averaging when we sold at the high cost average per share $3.89 45,500 shares. We have once again started to amass 58,500 shares dollar cost averaging $5.98 with the coming year potentially a 10 bagger or greater from its current closing price as of November 6, 2025 of $6.28 cents a share. The risk to reward simply is substantially supported by Capricor Therapeutics being the real deal for all their held licensed rights and held patents to say the least they will come into major payment meeting thresholds set gwithin their contractual rights and terms which are available by going to view all their SEC FILINGS. This security may actually make a substantial gain if they have found incredible success in their phase III HOPE III double blind study for their DMD candidate. I’m also using put option contracts to ensure the 99.999% money math in profitable trades as the name of the game is hedge all bets placed down on the table controlled by powerful market makers and swift moving hedge funds. Happy Friday Trading in setting up blockbuster swing-trade huge projected returns whe compared to many of the high flyers.
FDA tanks many stocks. CAPR ran way up and a rug pull. good to always lock in profits.
Where is the son of a bitch who put in several hundred thousand dollars on CAPR a few months ago in shares and call options? CAPR has only gone down since, down approx 50% from then.
NFLX, DFLY, WULF, SMR, CAPR, RDW, Z, NBIS, are my top picks. But buying the dips, of course. Everything else needs a correction.
CAPR...Set limit buy averagedowns to 6 just in case. When Duramiocel gets approved, shit's gonna rip.
CAPR is making a turnaround after their MS drug gained more FDA support last week (after they shockingly rejected it in early August). The pathway to approval is back on track anytime in Q4. If approved, double digits from current 7.50 is guaranteed, and moderate Price Target is 20-30 PT with its' and other approvals. Be careful, but load up on any dips.
The IV on CAPR options expiring tomorrow is 350-450%. Pretty sure tomorrow they’ll be releasing a statement detailing their path forward after they were issued a CRL by the FDA two months ago. Could potentially make money on either side, down or up.
CAPR: 28% short, key milestones in the next few days/weeks/months after 20 years of research, plenty of drama with the FDA, current sp $6.74, if approved it should be a $50-$70 stock, working on therapies for Duchenne muscular dystrophy, one of my biggest holdings. Not trying to make a case for it but just putting it out there
My CAPR, finally has some life. been holding this for a while
CAPR(almost penny) worth watching, its time to expect announcement of further progress of Demiocel approval/delay/reject with FDA after BLA
NRXP, UNCY, CAPR (the latter two have FDA CRL PRs coming this month, with good news)
Fyi CAPR already got CRL not sure why that's on this list. Love how it says 58% of approval yet it already got declined lmao
My plays for the day, lemme know what you guys think: CHYM, OKLO, VKTX, ACHR, CAPR, CRWV, FIG. To the moon we go
LLY, NOVO, VRTX, CAPR, UNH- all easy long plays that can also be swing traded on the way up with all health stocks undervalued, oversold for one reason or the other.
Been swing trading CAPR for a month, solid steady income. This might be the last day or two before back to double digits.
Not going to share my top picks, but on a side note, Im loving these Healthcare companies: NOVO, VRTX, LLY, UNH, CAPR, TKTX etc at the ridiculously cheap prices they're at. Just average down if they go lower, as most are at 2-5 year lows with upside.
If you are willing to average down a little if they fuck with them more, here's shorter term free money: NOVO LILLY CAPR PDYN RDWR SERV SMR SM BRBR VRTX Longer term free money: FLIX BBAI And tmrw's best play: ASTS
Great read OP, I’ve invested some money into this as a result. I was wondering what your thoughts were on the potential competition that could arise from CAPR? They have a drug in the trial phase that treats the same disease. They recently had their BLA rejected by the FDA, but their Phase 3 trial results should be out soon and if good the FDA would take another look at the drug. I feel like the results will turn out good at least from what I’ve read of them online and given their Phase 2 trial showed effectiveness.
The same thing can be said of $CAPR Capricor Therapeutics. VINAY blocked an effective trial, positive results, and crashed this company, their earnings tomorrow should spread more light on the topic. But after Lionsgate this is my second largest holding at this time. Good luck in your Sarepta play!
If you want strictly a baby bet for a 3 week window. I am taking odds on this. $CAPR Capricor https://preview.redd.it/lla0c51cs0hf1.jpeg?width=907&format=pjpg&auto=webp&s=70210d2f58d0d98b4292c834cc39e0fc193c1000
CAPR announced a presentation on Tuesday to discuss the next steps in its fight with the FDA. Let's see what happens. I sold puts and bought shares. Either $15.00 or $5.00. Low float.
All in on CAPR since market open today. DD: - Huge discount due to panic sell-offs and loss of confidence due to FDA pushback. - Awaiting clinical trial results expected in Q3. - Minimum 50% return by end of August (solely based on TA and optimism regarding trial results) Lets do this.
Should i buy CAPR? analyst are all for strong buy.
How is that CAPR guy doing rn?
Maybe I'm more sympathetic because I work in pharma, but I am not sure why people are hating. OP can both care about patients and invest in healthcare innovation like CAPR. In fact, without people like OP (shareholders), these companies wouldn't have the money to fund innovation. It's ridiculous to say that investing in the creation of medicine is inherently selfish just because he could profit from it.
Well I’m glad the idiots shilling CAPR and OPEN are dead
Got 1w puts at the top on CAPR. EZPZ.
CAPR went from 4.70 pre market to now almost double that lmao
Any idea why CAPR is down so much? Is it an opportunity?
🎆 I figure you guys will appreciate this little nugget: Two days ago, someone had $5.6 million riding on CAPR. He posted, "[Not Selling till $50M - lets ride!](https://www.reddit.com/r/wallstreetbets/comments/1lvke9e/not_selling_till_50m_lets_ride/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button)" And boy, what a ride it's been today! 🎢 Drops -62%. Then bounces +73% from her low. However, if OP was asleep and didn't buy the dip, he's down a cool $2 million.
Well... have you seen CAPR in the premarket today? 🎢 Drops -62%. Then bounces +73% from her low. However, if OP was asleep and didn't buy the dip, then he's down -35%, right now.
🎢 CAPR's wild premarket ride (don't touch this): Drops -62%. Then bounces +73% from her low.
Where is that guy who went all in on CAPR 🤣😂🤣😂🤣😂
I threw some calls into the watchlist when he posted so I could see what happens. I’d rather lose my money like usual rather than with CAPR I suppose ¯\_(ツ)_/¯
that guy who had 1 mil in CAPR idk now down 45% premarket. Maybe this is our chance to buy
has it ended? how big is his bet? lol lets see how your CAPR long do
Capricor Therapeutics, Inc. (CAPR) is a promising investment due to its lead drug, Deramiocel (CAP-1002), a cell therapy targeting heart problems caused by Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder affecting mostly boys, caused by a lack of dystrophin, a protein needed for muscle function. It leads to progressive muscle weakness, typically starting in early childhood. By their teens, many DMD patients lose the ability to walk (becoming non-ambulatory) and develop cardiomyopathy, a serious heart condition that weakens the heart muscle, leading to heart failure. No drugs currently exist to specifically treat DMD-related cardiomyopathy, leaving a critical gap in care. The global DMD treatment market is expected to reach $7.4 billion by 2034, with the non-ambulatory population—those who can no longer walk—representing a significant portion, estimated at over 50% of DMD patients by their mid-teens. This group, roughly 30,000 patients in the U.S. and Europe combined, drives a substantial market opportunity, with Deramiocel’s addressable market projected at $5.5 billion by 2032 due to its focus on cardiomyopathy. The FDA will decide on Deramiocel’s approval by August 31, 2025, and the drug has shown it’s safe and effective in trials. It has special FDA statuses, including Priority Review, Orphan Drug, and Rare Pediatric Disease designations, boosting its approval chances. An Advisory Committee (AdCom) meeting planned for late July 2025 was canceled, suggesting the FDA may not need further input, often seen as a positive sign. A late-cycle meeting with the FDA is set for next week to finalize review details. In the worst-case scenario, the FDA might request data from the ongoing HOPE-3 trial, but this will be available in August 2025, ready to share if needed, minimizing delays. Capricor’s partnership with Nippon Shinyaku (NS) is a major strength, providing $20 million upfront, a $15 million stock investment at a 20% premium, up to $715 million in future payments, and double-digit royalties. In September 2024, a binding letter of intent (LOI) was signed with NS for exclusive commercialization and distribution of Deramiocel in Europe (covering the EU, UK, and other regional countries), with Capricor handling development and manufacturing and NS managing sales. This leverages NS’s expertise in rare diseases and their DMD drug, Viltepso, to expand Capricor’s market reach. Capricor’s StealthX technology for vaccines and other treatments also adds future growth potential. Recent comments from FDA leaders Martin Makary and Vinay Prasad are encouraging. Makary supports an easier approval process for rare disease drugs like Deramiocel, using simple trial results. Prasad, who oversees FDA drug reviews, backs quick access to rare disease drugs and is open to using real-world data to confirm effectiveness post-approval, reducing hurdles for Deramiocel. Sarepta Therapeutics, a competitor, is facing issues with its DMD drug Elevidys after two patients died from liver problems, raising safety concerns about gene therapies. These therapies aim to replace the missing dystrophin protein but can cause serious side effects. Deramiocel, using cells to reduce inflammation and support heart health, is safer, potentially making it a preferred choice for doctors and the FDA, especially for non-ambulatory patients with cardiomyopathy who need safer options. Capricor has plenty of cash and no debt, enough to last beyond any potential FDA delays. If Deramiocel is approved, they could sell a Priority Review Voucher (PRV) for about $150 million and receive an $80 million payment from NS. These funds mean Capricor won’t need to sell more shares, avoiding dilution that could lower the stock’s value. The best part is that Deramiocel isn’t a one trick pony and the company has big plans to expand this product to treat other diseases already with the FDAs blessing
Soon your CAPR will be CRAP.
Did my full dd on CAPR. Asked chatgpt a solid 4-5 questions. I'm in🥱
I personally think SRPT is a safer bet because Sarepta is a commercial stage whereas Capricor is only a clinical stage. That being said, I still wouldn't be too surprised if CAPR does like 2x from here in short term.
Bro said $50mm like it’s no CAPR 💀.
zooming out, CAPR doesnt look so well. $2875 was its max, and i dont see it getting back.
Martin Shkreli is short on CAPR, that is all you need to know. Matt Nachtrab lost 70 million with SAVA while Shkreli made a million shorting SAVA
CAPR, PCT, and NGENF shares you're welcome
Right there with you buddy!!! CAPR CADL TGTX SRPT for the win !!!!
**TLDR:** He’s shorting $CAPR because he sees red flags — like the lack of Phase 3 data in the BLA, the canceled FDA advisory meeting, and concerns about a team member’s track record. He also has firsthand experience treating DMD patients and doesn’t believe any therapy can meaningfully change outcomes. I pushed back with the following: * **Deramiocel has shown real, statistically significant clinical benefit** (not just biomarkers or surrogates), including slowed functional decline and preserved cardiac function. * **FDA has approved weaker DMD drugs** on far thinner data, and they’ve engaged positively with Capricor (RMAT status, no review issues, passed inspection). * **The canceled AdCom is more likely bullish than bearish** — no controversy means no need for external input. * The safety profile is clean, and it’s the **first-ever drug to directly target DMD cardiomyopathy**, a fatal complication for which there’s currently zero treatment. * Shorting here could backfire hard if approval comes on time or if HOPE-3 data surfaces early. In short: The need is urgent, the data is strong, and FDA precedent heavily favors approval. I see 60–70% odds it gets approved by the Aug 31 PDUFA date.
Ya realize the DMD community (PPMD, CureDuchene) are supporting CAPR, even sit on their Board, right?
I have been super bearish on CAPR, but with the SRPT news this could be a legit option
Wanna DM me and talk about your thesis here? I’m short $CAPR. I’m a board licensed medical professional that has been working with individuals diagnosed with muscular dystrophy for the last 2.5-3 years. I don’t see this getting approval based on my face-to-face interventions I’ve completed with this population.
CAPR, tiny biotech with big short term and long term potential, no waiting, you’ll know by the end of August
Also thinking about taking a long position on CAPR. I have a weight towards CRL over any form of approval, but the implied odds seem worth it. I've been trying to figure out though, what did you make of the cancelling of the ad com and suspension of Verdun. Markets clearly seem to think quite bearish, and the bear hypothesis of Prasad and his new CBER demanding an increased evidentiary standard seems to fit nicely. I don't know if I completely buy it though, for other reasons. Do you have any thoughts?
But right now I’m holding CAPR
PCT, NGENF, and CAPR are my straight gambles rn. However, I make Ralph Wiggum look like Einstein.
Don't know about PCT or NGENF but CAPR was nice today and I sold and last I checked it was up in futures. Also, got in on ASTS late-ish ($50) and feel uneasy because nothing can go vertical this long.
Maybe I shouldn't have sold $30K in ASTS shares to buy $10k each in PCT, NGENF, and CAPR...
i spend $10k each on PCT, CAPR, and NGENF shares today (ralph wiggum voice)
I need confirmation bias for throwing $10k each at shares of PCT, NGENF, and CAPR...sold my ASTS for it...
Just sold about $40k of ASTS in my gambling account and threw it at PCT, NGENF, and CAPR...my only DD is that PCT sounds dope af and my boy is a pharma bro and NGENF and CAPR are his two largest positions by far NFA Ralph Wiggum beats a tambourine inside my skull
just shot my wad on PCT and CAPR
just bought $10k in CAPR and PCT shares...my spirit animal is ralph wiggum
Interesting to see how the FDA is reassessing its approach to gene therapies. Do you think this change will benefit more biotechs besides CAPR?
I've lost $12k between CAPR, RDDT, LUNR, and PCT only one I see possibly coming back in the next 2 years is RDDT. Such is life.
I am new to the stock market, but purchased CAPR about a month or 2 ago. It has been going down. While I don't understand much of your post (I will research some of your terminology and phrases - thanks), it seems your assessment is that CAPR is poised to go up quite a bit, is that right??? And, are you saying that when it does, one should take profits/sell soon thereafter?
good day for the DMD community! Let's go CAPR
Pick up some CAPR before is too late
Tomorrow CAPR will fly like an Italian CAPR-ONI
😃 Now is the time for street guy, $CAPR!😎🤟🇺🇲
I wonder if OP is legit, I was looking into CAPR analysis and I thought he wan onto something until I came across this post on his profile. SPR went down all the way to $24 after this post, and is trading at $33 currently. Makes me question the legitimacy and intent of your posts. @androidmj
So apparently, the shares of many vaccine makers, including Moderna ([MRNA](https://www.tipranks.com/stocks/mrna)), Novavax ([NVAX](https://www.tipranks.com/stocks/nvax)), and BioNTech ([BNTX](https://www.tipranks.com/stocks/bntx)) (BTNX), and gene therapy developers, including Sarepta ([SRPT](https://www.tipranks.com/stocks/srpt)), Solid Biosciences ([SLDB](https://www.tipranks.com/stocks/sldb)), Taysha Gene Therapies ([TSHA](https://www.tipranks.com/stocks/tsha)), Capricor Therapeutics ([CAPR](https://www.tipranks.com/stocks/capr)), and Crispr Therapeutics ([CRSP](https://www.tipranks.com/stocks/crsp)), are moving lower following the resignation of Peter Marks from the Food and Drug Administration. Marks was viewed as one of the biggest FDA advocates of cell and gene therapies. [Vaccine, gene therapy makers fall after Peter Marks resignation - TipRanks.com](https://www.tipranks.com/news/the-fly/vaccine-gene-therapy-makers-fall-after-peter-marks-resignation)
but while they do this, isn't they who got hurt as well by reducing the amount of money they posses with the stakes they already had accumulated towards CAPR?
This is what I was wondering too. Why on earth is the stock dropping so bad given generally positive newsflow coming from CAPR lately?
Depends on your option strategy. My portfolio is currently entirely leaps on KULR, CAPR, RIOT and SOXL as of last Friday. I'll probably average down in April and sit on my hands till Christmas.
**UPDATE:** CAPR has announced an **earnings date (March 19)** and released a new investor deck that includes a **target reimbursement price of $1.2M per year**—slightly higher than my initial expectations. Key takeaways from **Capricor’s March 2025 Investor Deck**: 📌 **15,000–20,000** DMD patients in the U.S. 📌 **200,000** DMD patients worldwide 📌 **$27B+** estimated market size by 2030 📌 **Target reimbursement price** expected to be **similar or higher** than exon-skipping therapies (**$1.2M/year**) (Source: [CAPR Investor Deck – March 2025](https://d1io3yog0oux5.cloudfront.net/_5945d8f28f1592eeef48b5ce9959442b/capricor/db/2227/21450/pdf/CAPR+March+2025.pdf)) I've also added to my position: https://preview.redd.it/9of1karzl4oe1.png?width=1290&format=png&auto=webp&s=b3f7ed73921b5165e965548c027cd2d289764773
Yeah, in a market that’s been tanking, CAPR has been showing relative strength instead of breaking down with everything else. Given the high short interest (\~20%), you’d expect it to bleed more if there wasn’t demand absorbing selling pressure. Could be accumulation, shorts covering on the low, or just strong hands refusing to sell. Either way, it’s not trading like a weak stock—which is worth noting heading into earnings and PDUFA hype.
From Capricor’s March 2025 Investor Deck: • 15,000–20,000 DMD patients in the U.S. • 200,000 DMD patients worldwide • $27B+ market size by 2030 • Target reimbursement price expected to be similar or higher than exon-skipping therapies [investor deck](https://d1io3yog0oux5.cloudfront.net/_5945d8f28f1592eeef48b5ce9959442b/capricor/db/2227/21450/pdf/CAPR+March+2025.pdf)
CAPR has been holding up rather well. So that is what makes you think someone's accumulating?
# **TLDR** --- **Ticker:** CAPR **Direction:** Up **Prognosis:** Buy September $15 Calls **Author's Position:** 910 September $15 Calls, currently showing a $29,506 day gain. **Price Target:** $75-$200+ per share based on potential Deramiocel pricing and revenue. **Catalyst:** March 19th earnings call. Expect updates on cash runway, FDA review, and commercialization details.
The market might be underestimating the FDA's Priority Review significance and the lack of competition. If Deramiocel gets approved, CAPR could see a significant upside. The high short interest could also lead to a squeeze if sentiment shifts.